[Pubmed] Navigating coexisting autoimmunity and immunodeficiency in thymoma: a case report of TAMA, Good's syndrome, and

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6500
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Mac OS X Chrome

[Pubmed] Navigating coexisting autoimmunity and immunodeficiency in thymoma: a case report of TAMA, Good's syndrome, and

Message par RSS-Bot »


Front Immunol. 2026 Sep 9;17:1916812. doi: 10.3389/fimmu.2026.1916812. eCollection 2026.

ABSTRACT

The coexistence of thymoma-associated multiorgan autoimmunity (TAMA) and Good's syndrome creates a challenging clinical scenario in which autoimmunity and profound immunodeficiency occur simultaneously. Here, we report a 37-year-old female with invasive WHO Type B3 thymoma and myasthenia gravis (MG) who developed progressive erythroderma-like skin lesions with graft-versus-host disease-like interface dermatitis. Immunological evaluation revealed marked hypogammaglobulinemia, absent circulating B cells, reduced CD4+ T cells, and an inverted CD4+/CD8+ ratio. During a subsequent myasthenic crisis, severe immune dysfunction and active pulmonary infection were already present. Because conventional rapid immunomodulatory options were limited, efgartigimod and eculizumab were administered sequentially. The pulmonary infection continued to progress, and the patient ultimately died. This case highlights the importance of immune and infection risk assessment before potent immunomodulatory therapy.

PMID:42780472 | PMC:PMC13597385 | DOI:10.3389/fimmu.2026.1916812


Source: https://pubmed.ncbi.nlm.nih.gov/4278047 ... 7&v=2.20.1
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »